New nasal spray aims to stop asthma Flare-Ups triggered by common cold

NCT ID NCT07488897

Recruiting now Disease control Sponsor: RIGImmune Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a nasal spray called RIG-101 in healthy people and those with asthma. First, it checks safety and tolerability. Then, asthma participants receive the spray daily and are exposed to a cold virus to see if it prevents asthma worsening. The trial is recruiting 82 adults aged 18-65.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RIG-101 (nasal spray)
What this could lead to: If successful, this could point toward a new treatment to prevent asthma flare-ups triggered by common cold viruses.
What could go wrong: This is an early combined Phase 1-2 trial with only 82 participants, so safety and efficacy are not yet proven. The viral challenge part is artificial and may not reflect real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma status asthmaticus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA EXACERBATION HEALTHY ADULT PARTICIPANTS SAFETY AND EFFICACY

Contacts and locations

Show contact details

Locations

Medicines Evaluation Unit
RECRUITING

Manchester, M23 9QZ, United Kingdom

Contact Email: •••••@•••••
Virtus Respiratory Research Ltd
NOT_YET_RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.